Open access
Open access
Powered by Google Translator Translator

HIV

A highly virulent variant of HIV-1 circulating in the Netherlands.

7 Feb, 2022 | 08:42h | UTC

A highly virulent variant of HIV-1 circulating in the Netherlands – Science

Commentaries:

New highly virulent and damaging HIV variant discovered in the Netherlands – University of Oxford

Highly virulent HIV variant found circulating in Europe – Nature

 

First patients vaccinated in clinical trial of HIV experimental vaccine that uses Moderna’s mRNA technology.

4 Feb, 2022 | 08:25h | UTC

First patients vaccinated in clinical trial of HIV experimental vaccine that uses Moderna’s mRNA technology – CNN

 

New AAP Guidance recommends routine HIV screening to all youth 15 years or older.

8 Jan, 2022 | 23:13h | UTC

Adolescents and Young Adults: The Pediatrician’s Role in HIV Testing and Pre- and Postexposure HIV Prophylaxis – Pediatrics

Commentary: Pediatricians Can Play Key Role in HIV Testing, Prophylaxis – HealthDay

 

FDA approves first injectable treatment for HIV pre-exposure prevention.

8 Jan, 2022 | 23:04h | UTC

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention – U.S. Food & Drug Administration

Commentaries:

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases

A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR

Related:

CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents

Study Shows High Burden of STI Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection

USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection

British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)

New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required

 

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

8 Jan, 2022 | 23:07h | UTC

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Easy-to-take medicine better at suppressing HIV in children – University College London

 

Commentaries on Twitter

 

Global estimates of viral suppression in 31 countries shows too many people with HIV fail to achieve durable viral suppression.

1 Dec, 2021 | 08:41h | UTC

News Release: Too many people with HIV fail to achieve durable viral suppression – NIH News Releases

Original Study: Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries – The Lancet HIV (link to abstract – $ for full-text)

 

WHO releases HIV drug resistance report 2021.

25 Nov, 2021 | 10:36h | UTC

News Release: WHO releases HIV drug resistance report 2021 – World Health Organization

Report: HIV drug resistance report 2021 – World Health Organization

Fact Sheet: HIV Drug Resistance – World Health Organization

 

Commentary on Twitter

 

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019.

29 Sep, 2021 | 09:56h | UTC

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019 – The Lancet HIV

 

Commentary on Twitter (thread – click for more)

 

How COVID is derailing the fight against HIV, TB and malaria.

15 Sep, 2021 | 09:01h | UTC

How COVID is derailing the fight against HIV, TB and malaria – Nature

Related:

How COVID hurt the fight against other dangerous diseases

World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis

WHO: Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1

 

RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.

12 Aug, 2021 | 08:51h | UTC

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women – New England Journal of Medicine

 

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

23 Jul, 2021 | 10:25h | UTC

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Dolutegravir Confirmed as Effective Second-Line HIV Therapy; Recycling Tenofovir Noninferior to Zidovudine – Medscape (free registration required)

 

WHO warns that HIV infection increases risk of severe and critical COVID-19.

20 Jul, 2021 | 10:24h | UTC

News release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization

Report: WHO report on clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with SARS-CoV-2 infection

Related: M-A: Epidemiology and outcomes of COVID-19 in HIV-infected individuals – HIV is a significant risk factor for acquiring SARS-CoV-2 infection and is associated with a higher risk of mortality.

 

Commentary on Twitter (thread – click for more)

 

WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring.

18 Jul, 2021 | 23:22h | UTC

WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring – World Health Organization

Guideline: Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach – World Health Organization

 

New WHO report highlights global progress on reducing HIV, viral hepatitis and sexually transmitted infections and signals need for renewed efforts to reach 2030 targets.

21 May, 2021 | 08:33h | UTC

News Release: New report highlights global progress on reducing HIV, viral hepatitis and sexually transmitted infections and signals need for renewed efforts to reach 2030 targets

Original report: Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Podcast: HIV for the Pediatrician

13 May, 2021 | 05:47h | UTC

HIV for the Pediatrician – The Cribsiders Pediatric Medicine

 

Overview of SARS-CoV-2 infection in adults living with HIV – Low CD4 cell counts, or untreated HIV infection is associated a more severe clinical course

28 Apr, 2021 | 08:32h | UTC

Overview of SARS-CoV-2 infection in adults living with HIV – The Lancet HIV

 

Commentary on Twitter

 

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

2 Apr, 2021 | 09:15h | UTC

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: ART in pregnant women living with HIV – The Lancet

 

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

21 Mar, 2021 | 21:34h | UTC

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition – New England Journal of Medicine (link to abstract – $ for full-text)

 

WHO Guideline: Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring

18 Mar, 2021 | 08:55h | UTC

Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring – World Health Organization

News release: WHO publishes new clinical and service delivery recommendations for HIV prevention, treatment and care

 

U.S. Guidelines panel recommendation for long-acting injectable antiretroviral regimen in adults and adolescents with HIV

28 Feb, 2021 | 20:34h | UTC

HHS Adults and Adolescents Antiretroviral Guidelines Panel Recommendation for the Long-Acting Injectable Antiretroviral Regimen of Cabotegravir and Rilpivirine – HIV.gov

What’s New in the Guidelines? Panel’s Recommendation for Long-Acting Injectable Cabotegravir and Rilpivirine in Persons with HIV

 

WHO recommends the Dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection

28 Jan, 2021 | 01:22h | UTC

WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection – World Health Organization

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.